Ali Ardakani is a visionary biotech executive, entrepreneur, and corporate strategist with over 20 years of leadership experience across the life sciences sector. His career spans innovation in oncology, ophthalmology, immunology and medical devices, guiding projects from early research through to FDA approvals and global commercialization.
Ali is the Founder & Managing Director of Novateur Ventures, where he partners with companies worldwide to accelerate life science breakthroughs. He is also the Co-Founder & CEO of Optigo Biotherapeutics, an ophthalmology R&D company advancing novel therapies. Previously, he served as Senior Vice President of Device and Business Development at Beyond Air (NASDAQ: XAIR), where he played a pivotal role from early-stage development to public offering and global expansion.
A passionate advocate for the life sciences community, Ali is the Past Chair of the Board of Directors of Life Sciences British Columbia and an Associate at Creative Destruction Lab. Throughout his career, Ali has contributed to the success of multiple mergers and acquisitions, licensing deals, and financing rounds, and remains committed to building collaborations that transform patient care. His upcoming role on the BC Cancer Foundation Board reflects his deep dedication to advancing innovation, impact, and hope for patients and families across British Columbia and beyond.
